Candel Therapeutics Announces Presentation at Global Healthcare Conference
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a biopharmaceutical company dedicated to creating multimodal biological immunotherapies for cancer treatment, is set to present at a significant global healthcare event. This presentation will feature insights from Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and CEO, showcasing the company’s latest developments in the fight against cancer.
About the Upcoming Presentation
The Candel Therapeutics presentation is scheduled during the Jefferies Global Healthcare Conference, an event renowned for addressing breakthrough health innovations. Attendees can look forward to hearing from Dr. Tak on Tuesday, November 18, with a focus on the company’s unique therapeutic strategies. This platform is expected to provide valuable updates on Candel's research status and future initiatives.
Presentation Logistics
During the conference, Dr. Tak will present from 8:00-8:25 AM GMT, allowing attendees to gain insights into Candel's promising pipeline and innovative approaches. This session aims to foster understanding of the company’s cutting-edge work on viral immunotherapies, aimed at eliciting strong immune responses to combat various cancers.
Exploring Candel’s Innovative Immunotherapy Platforms
Candel Therapeutics is particularly known for its pioneering work in developing off-the-shelf viral immunotherapy treatments. These therapies are designed to trigger personalized immune responses, significantly enhancing the potential to fight different cancer types. The company employs advanced technologies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, representing new frontiers in cancer immunotherapy.
Clinical Successes
Recently, Candel has achieved notable success in its clinical trials. For instance, the company completed successful phase 2a trials of its lead candidate, CAN-2409, in the treatment of non-small cell lung cancer and pancreatic cancer. Furthermore, a pivotal phase 3 clinical trial of CAN-2409 has shown promising results in localized prostate cancer, drawing attention from regulatory bodies.
Regulatory Designations and Future Developments
Candel Therapeutics has garnered Fast Track Designation from the FDA for CAN-2409 aimed at treating patients resistant to standard therapies, signaling a significant step forward in cancer treatment accessibility. Enhancements to the drug have also gained Orphan Drug Designation, allowing for a prioritization in development for rare conditions.
Ongoing Initiatives
Currently, CAN-3110, derived from the HSV platform, is in phase 1b trials for high-grade glioma. The preliminary findings from these trials have raised interest within the biomedical community, and the future appears promising given the potential impact of these therapies. Additionally, Candel's enLIGHTEN™ Discovery Platform is a leading-edge tool that leverages human biology to uncover novel viral therapies for solid tumors.
Getting Involved and Learning More
For those interested in Candel Therapeutics, further information can be found through their official website. The company is committed to keeping investors and the public informed about their research and development advancements. With continued growth and ongoing clinical trials, Candel is positioned at the forefront of transformative cancer therapy.
If you are interested in the latest treatments in cancer therapy or wish to understand more about Candel Therapeutics and its groundbreaking initiatives, attending the upcoming presentation at the Jefferies conference could provide crucial insights into the company’s future directions and innovations.
Frequently Asked Questions
What is Candel Therapeutics' primary focus?
Candel Therapeutics is focused on developing multimodal biological immunotherapies to help patients combat cancer.
Who will be presenting at the Jefferies Global Healthcare Conference?
Paul Peter Tak, M.D., Ph.D., the President and CEO of Candel Therapeutics, will be presenting.
What are the key products developed by Candel Therapeutics?
Key products include CAN-2409 and CAN-3110, aimed at treating various forms of cancer.
What regulatory designations has Candel achieved?
Candel has received Fast Track and Orphan Drug Designations from the FDA for certain therapies.
How can I learn more about Candel Therapeutics?
More information can be found on Candel's official website, where updates and details about ongoing studies are provided.